Teva’s Acquisition Of Barr Will Boost Research For Molecules Large And Small
Executive Summary
Teva expects to double its R&D capabilities with the acquisition of Barr, executives from both firms said during a July 21 luncheon in New York
You may also be interested in...
Teva’s At-Risk Launch Of Pulmicort Generics May Cost It Exclusivity
Teva's exclusivity clock may already be ticking following the short-lived launch of a generic version of AstraZeneca's Pulmicort. Generic sales for the product are now suspended by court order with a hearing on the preliminary injunction scheduled for Nov. 25
Teva’s At-Risk Launch Of Pulmicort Generics May Cost It Exclusivity
Teva's exclusivity clock may already be ticking following the short-lived launch of a generic version of AstraZeneca's Pulmicort. Generic sales for the product are now suspended by court order with a hearing on the preliminary injunction scheduled for Nov. 25
Follow-On Biologics Market Unfolding: Big Pharma Signals An Interest
Large pharmaceutical and biotechnology companies will start openly developing follow-on biologics once Congress passes legislation authorizing an abbreviated approval pathway, Cowen & Co. analyst Ken Cacciatore predicted